Abstract
This study did not find any clinically significant change in serum markers of renal function in the one month after intravitreal ranibizumab or aflibercept. It did, however, find a non-significant rise in creatinine with aflibercept, that was not seen with ranibizumab.
Original language | English |
---|---|
Pages (from-to) | 1770-1772 |
Number of pages | 3 |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |
Volume | 38 |
Issue number | 7 |
Early online date | 10 Feb 2023 |
DOIs | |
Publication status | Published - 30 Jun 2023 |